StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
RENX.L$2.00+11.11%
Fair $2.00+0.0%

RENX.L

Renalytix Plc

Healthcare / Health Information ServicesLSE

$2.00

+0.20 (+11.11%)

Fairly Valued+0.0%Fair Value $2.00Fund rank 31/100 · Data gapFallback financials|
SA 26/D
F-Score: 6/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 33% · confianza 25%

FCF escenarios

weak_data · normalized FCF $-29.8M · quality 75.7/100

Data gap 31/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 40/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

26/100

D

Piotroski

6/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. ROE is 2.9%, below the 5% threshold
Thesis & Journal · RENX.LLocal privado en este navegador · Renalytix Plc
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$9M

P/E

N/A

•

EV/EBITDA

N/A

•

ROE

291.4%

↑

Gross Margin

40.0%

↓

Debt/Equity

-1.19

↓
52-Week Range$2
$2$16

TradingView lightweight chart

RENX.L price, volumen y niveles de valoración

Último $2.000Periodo -98.3%
Fair value: $2.000

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+0.3%

FCF CAGR

—

FCF margin

-596.7%

FCF / Net income

0.88x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $3.0M · net income $-20.4M · FCF $-17.9M

2022-FY → 2025-FY

Gross margin

40.0%+10.6% pts

Operating margin

-573.3%+1217.3% pts

Net margin

-680.0%+844.4% pts

FCF margin

-596.7%+971.9% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$3.0M$3.0M$2.3M$3.4M$3.0M
Net Income$-20.4M$-20.4M$-45.5M$-45.6M$-45.3M
EBITDA$-21.3M$-21.3M$-43.0M$-41.7M$-52.7M
EPS-0.07-0.07-0.31-0.56-0.82
Gross Margin40.0%40.0%8.7%21.2%29.4%
Operating Margin-573.3%-573.3%-1326.1%-1240.7%-1790.7%
Net Margin-680.0%-680.0%-1978.3%-1340.2%-1524.4%
Balance Sheet
Debt/Equity-1.19-1.19-0.941.740.40
Current Ratio1.571.57———
Cash Flow
Free Cash Flow$-17.9M$-17.9M$-29.8M$-34.1M$-46.6M
Returns
ROE291.4%291.4%505.6%-654.6%-147.9%
Valuation
P/B———1386.49255.91
Growth & Yield
Revenue Growth30.4%30.4%-32.4%14.6%—
EPS Growth77.4%77.4%44.6%31.7%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -72.4%

Total return

-72.4%

Start / end P/E

n/dx → n/dx

EPS bridge

-0.31 → -0.07

Residual

-72.4%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term-72.4%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.